FDA decision on relacorilant for Cushing’s expected by year’s end
The U.S. Food and Drug Administration (FDA) has accepted an application from Corcept Therapeutics seeking the approval of relacorilant as a treatment for people with endogenous Cushing’s syndrome. A decision from the FDA is now expected by Dec. 30, according to the company. “The FDA’s acceptance of our…